Results 121 to 130 of about 2,363 (167)

Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential. [PDF]

J Med Chem
Raucci A, Zwergel C, Valente S, Mai A.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Polyamines prevent DFMO-mediated inhibition of angiogenesis

Cancer Letters, 1994
Tumor growth mainly depend on formation of new blood vessels. DFMO (alpha-difluoromethylornithine), an inhibitor of polyamine biosynthesis, inhibits tumor growth in many animal tumors. Our investigation was to evaluate the requirement of polyamines for induction of angiogenesis by tumor cells and spleen lymphocytes from tumor-bearing mice.
SLOBODANKA Klein, Martin Monte, Lilia Davel   +2 more
exaly   +4 more sources

Maintenance DFMO Increases Survival in High Risk Neuroblastoma [PDF]

Scientific Reports, 2018
AbstractHigh risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent ...
Giselle L Saulnier Sholler, William Ferguson, Kathleen Neville   +2 more
exaly   +5 more sources

Chemoprevention in prostate cancer: The role of difluoromethylornithine (DFMO)

Journal of Cellular Biochemistry, 1992
The polyamines are normal cell constituents considered to have an important role in the regulation of proliferation and differentiation. DFMO is an irreversible, enzyme-activated, suicide inhibitor of ornithine decarboxylase (ODC), the enzyme responsible for the first and rate-limiting step in mammalian polyamine synthesis.
Dov Kadmon
exaly   +3 more sources

DFMO Carbon Dots for Treatment of Neuroblastoma and Bioimaging

ACS Applied Bio Materials, 2022
Neuroblastoma (NB) is a pediatric malignancy affecting the peripheral nervous system. Despite recent advancements in treatment, many children affected with NB continue to submit to this illness, and new therapeutic strategies are desperately needed. In recent years, studies of carbon dots (CDs) as nanocarriers have mostly focused on the delivery of ...
Suraj Paudyal, Frederic Anthony Vallejo, Emel Kirbas Cilingir, Yiqun Zhou, Keenan J. Mintz, Yelena Pressman, Jun Gu, Steven Vanni, Regina M. Graham, Roger M. Leblanc   +9 more
openaire   +2 more sources

Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma

Cancer Chemotherapy and Pharmacology, 2021
Neuroblastoma (NB) is the most common extracranial solid tumor in children. Interference with the polyamine biosynthesis pathway by inhibition of MYCN-activated ornithine decarboxylase (ODC) is a validated approach. The ODC inhibitor α-difluoromethylornithine (DFMO, or Eflornithine) has been FDA-approved for the treatment of trypanosomiasis and ...
Chad R. Schultz, Matthew A. Swanson, Thomas C. Dowling, André S. Bachmann   +3 more
openaire   +2 more sources

Inhibition of DFMO-induced audiogenic seizures by chlordiazepoxide

Life Sciences, 1993
Mice given 1% alpha-difluoromethylornithine (DFMO) in the drinking water for 5 weeks developed a hyperactive behavior characterized by uncontrolled running upon stimulation with noise. The running was followed by seizures and sometimes death. These behaviors are characteristic of audiogenic seizures. Strain differences in susceptibility to DFMO-induced
K E, Gerrish, D J, Fuller, E W, Gerner, H L, Gensler   +3 more
openaire   +2 more sources

Delayed, Reversible Hearing Loss Caused by Difluoromethylornithine (DFMO)

Laryngoscope, 2001
AbstractObjectives/Hypothesis Difluoromethylornithine (DFMO) is an anticancer experimental drug that is ototoxic. The objectives of these three experiments were to: 1) determine a dose and dosing schedule of DFMO that produces significant hearing loss (HL) in newborn gerbils; 2) compare the HL level for control and newborn gerbils receiving daily ...
exaly   +3 more sources

Chemoprevention of Prostate Carcinogenesis by DFMO and/or Finasteride Treatment in Male Wistar Rats

Tumori, 2002
In the present study the chemopreventive activities of DFMO, the irreversible inhibitor of ornithine decarboxylase, and finasteride, the inhibitor of prostatic 5a-reductase, against the development of chemically induced prostate adenocarcinoma by methylnitrosourea/testosterone propionate in male Wistar rats were investigated.
Amr Y Esmat, Mahmoud M Said
exaly   +3 more sources